Lifesci Acquisition II Corp.: directors' dealings · United States · SEC (Form 4)

About Lifesci Acquisition II Corp.

Lifesci Acquisition II Corp. was a special purpose acquisition company, or SPAC, incorporated in Delaware in December 2019 and organized to complete a merger, share exchange, asset acquisition, stock purchase, recapitalization, or similar business combination with one or more operating businesses. Its original prospectus made clear that the company was not a traditional operating business; instead, it was a capital-markets vehicle designed to identify and acquire a target, with an investment focus on North America and the healthcare sector. The company was listed on the NASDAQ under the symbol LSAQ, placing it squarely in the U.S. public-equity market. Its historic filing address was in New York, reflecting the company’s proximity to the U.S. financial and healthcare investment ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819113/000110465920128489/tm2025441d9_424b4.htm?utm_source=openai)) From a business-model standpoint, LifeSci Acquisition II did not sell products or operate a commercial platform on its own. Its role was to raise IPO proceeds, search for a target, negotiate a transaction, and then transition the listed shell into an operating public company. That process was completed in 2021, when LifeSci Acquisition II combined with Science 37. In practical terms, the legacy SPAC entity became the public listing vehicle for Science 37 rather than a standalone enterprise with its own ongoing operating lines. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819113/000110465922051218/tm2210439-3_424b3.htm?utm_source=openai)) Science 37 is the company that emerged from that transaction and is the relevant operating business associated with the former LifeSci Acquisition II structure. Science 37 describes itself as a patient access company and a clinical research site for decentralized clinical trials, enabling study participation through home-based visits, telemedicine investigators, mobile nurses, and integrated technology workflows. Its platform is aimed at improving recruitment, retention, diversity, and data capture in clinical studies, particularly for sponsors in pharmaceutical, biotech, and broader life sciences markets. The company also highlights specialized capabilities across therapeutic areas such as oncology and other complex indications. ([science37.com](https://www.science37.com/?utm_source=openai)) Geographically, Science 37 is headquartered in the United States, with a corporate base in the Research Triangle region of North Carolina after relocating from California. The company’s direct-to-patient model supports clinical trial execution across the U.S. and, based on its own disclosures, is built to scale across broader North American and international sponsor demand where regulatory requirements allow. This is important for investors because the addressable market is not limited to a single therapeutic niche; rather, it sits at the intersection of clinical operations, digital health, and outsourced research services. ([science37.com](https://www.science37.com/direct-to-patient-site/?utm_source=openai)) Recent company news underscores that Science 37 continues to invest in specialization and operational breadth. In 2026 it announced a dedicated pediatrics department, while its news flow also included new leadership appointments and recognition for site innovation. These developments suggest ongoing efforts to deepen capabilities, broaden therapeutic coverage, and reinforce its market positioning as a decentralized-trials platform. For equity investors, the key takeaway is that the former Lifesci Acquisition II Corp. should be viewed primarily as the SPAC origin of a U.S.-listed healthcare services company on NASDAQ, not as a legacy blank-check issuer with an independent operating franchise. ([science37.com](https://www.science37.com/news/?utm_source=openai))